A new generation of melanoma researchers
15 February 2018
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
James Wilmott is part of the new generation of melanoma researchers, and was drawn to Melanoma Institute Australia by the direct link between clinical research and patient care. He knew this was an area in which he could really make a difference.
“Being a scientist, you don’t often see patients in your day to day work,” he explains. “I thought by working at Melanoma Institute Australia, where it brings together clinical research and basic science, I could see patients as well as do the cutting edge research.”
Dr Wilmott’s work focuses on why 15 to 39 year olds are being diagnosed with melanoma at a higher rate than any other cancer. Early results of whole genome sequencing of tumours from these patients show 90% of all mutations in a 16 year old patient are caused by the sun – a surprising result given the young age of the patient.
“It is surprising because it looks similar to what we see in adults… and the accumulation over a lifetime,” Dr Wilmott says. “They must have some sort of genetic abnormalities that make them more susceptible to UV damage. If we can pinpoint the genes that make them susceptible, and then find them in other young patients, we can target them with preventative measures to prevent them from getting melanoma in the first place.
“It’s an exciting time to be involved in melanoma research. We’re making great inroads into melanoma care,” he said.
James’ is the latest in a series of emotive videos launched by Melanoma Institute Australia, showing the impact of melanoma on everyday Australians. Watch his story here and join him in the fight against melanoma by signing up for a Melanoma March event near you.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.